To evaluate the potential risk of developing eating disorders in individuals using GLP-1 weight loss medications, particularly in the context of rising prescriptions.
Key Findings:
1.28% of GLP-1 users were diagnosed with an eating disorder within two years, indicating a concerning trend.
If one in eight Americans takes GLP-1s, over 420,000 could potentially develop an eating disorder, highlighting a public health concern.
There is a mechanistic overlap between obesity and anorexia that warrants further investigation to understand the underlying biology.
Interpretation:
The findings suggest a significant risk of eating disorders associated with GLP-1 medications, highlighting the urgent need for proactive screening and further research into the psychological effects of these drugs.
Limitations:
Current research on GLP-1s and eating disorders is limited, and further studies are needed to validate these findings.
The analysis is based on medical records, which may not capture all cases or nuances, potentially leading to underreporting.
Conclusion:
Physicians and stakeholders must prepare for the potential rise in eating disorders linked to GLP-1 medications, prioritize patient screening, and advocate for further research into the psychological impacts of these treatments.
In a target-trial emulation of more than 600,000 veterans, GLP-1 RA initiators saw fewer new substance use disorders—and patients with existing SUDs had fewer overdoses, hospitalizations, and deaths.
